Metoprolol – one drug, seven therapeutic indications Review article
Article Sidebar
Published:
Jun 30, 2017
Keywords:
metoprolol, cardioselective β-blocker, therapeutic indications
Main Article Content
Abstract
Metoprolol is a cardioselective β-blocker, devoid of internal sympathomimetic activity. It is one of the β-blockers with the most therapeutic indications. In selected indications it is recommended for children over 6 years of age and pregnant women. The sustained release formulation provides a steady therapeutic concentration for 24 h. Metoprolol can be safely used in patients with renal failure.
Article Details
How to Cite
Wydra, W., & Kuch , M. (2017). Metoprolol – one drug, seven therapeutic indications. Medycyna Faktow (J EBM), 10(2(35), 146-151. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2156
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Stankiewicz R.: The development of beta-blockers at Astra-Hassle and the technological systems of the Swedish pharmaceutical industry. W: Carlsson B. (red.): Technological systems and industrial dynamics. Kluwer Academic Publishers, 1997: 93-137.
2. MERIT-HF Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353(9169): 2001-2007.
3. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group: Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366(9497): 1622-1632.
4. [online: http://indeks.mp.pl/leki/desc.php?id=543].
5. Miller S., Matharu M.S.: Migraine is underdiagnosed and undertreated. The Practitioner 2014; 258(1774): 19-24.
6. Evers S., Afra J., Frese A. et al.: EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur. J. Neurol. 2009; 16: 968-981.
7. Owecki M.K., Łukasik M., Kozubski W.: Współczesne zasady farmakoterapii migreny. Nowiny Lekarskie 2011; 80(2): 116-125.
8. Loder E., Burch R., Rizzoli P. et al.: The 2012 AHS/AAN Guidelines for Prevention of Episodic Migraine: A Summary and Comparison With Other Recent Clinical Practice Guidelines. Headache 2012; 52: 930-945.
9. Kangasniemi P., Andersen A.R., Andersson P.G. et al.: Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 1987; 7(4): 231-238.
10. Steiner T.J., Joseph R., Hedman C., Rose F.C.: Metoprolol in the prophylaxis of migraine: parallel group comparison with placebo and dos-ranging follow-up. Headache 1988; 28: 15-23.
11. Ablad B., Dahlof C.: Migraine and b-blockade: modulation of sympathetic neurotransmission. Cephalalgia 1986; 6: 7-13.
12. [online: http://indeks.mp.pl/leki/desc.php?id=543].
13. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur. Heart J. 2013; 34: 2159-2219.
14. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Nadciśnienie Tętnicze w Praktyce 2015; 1(1): 1-70.
2. MERIT-HF Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353(9169): 2001-2007.
3. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group: Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366(9497): 1622-1632.
4. [online: http://indeks.mp.pl/leki/desc.php?id=543].
5. Miller S., Matharu M.S.: Migraine is underdiagnosed and undertreated. The Practitioner 2014; 258(1774): 19-24.
6. Evers S., Afra J., Frese A. et al.: EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur. J. Neurol. 2009; 16: 968-981.
7. Owecki M.K., Łukasik M., Kozubski W.: Współczesne zasady farmakoterapii migreny. Nowiny Lekarskie 2011; 80(2): 116-125.
8. Loder E., Burch R., Rizzoli P. et al.: The 2012 AHS/AAN Guidelines for Prevention of Episodic Migraine: A Summary and Comparison With Other Recent Clinical Practice Guidelines. Headache 2012; 52: 930-945.
9. Kangasniemi P., Andersen A.R., Andersson P.G. et al.: Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 1987; 7(4): 231-238.
10. Steiner T.J., Joseph R., Hedman C., Rose F.C.: Metoprolol in the prophylaxis of migraine: parallel group comparison with placebo and dos-ranging follow-up. Headache 1988; 28: 15-23.
11. Ablad B., Dahlof C.: Migraine and b-blockade: modulation of sympathetic neurotransmission. Cephalalgia 1986; 6: 7-13.
12. [online: http://indeks.mp.pl/leki/desc.php?id=543].
13. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur. Heart J. 2013; 34: 2159-2219.
14. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Nadciśnienie Tętnicze w Praktyce 2015; 1(1): 1-70.